Type 2 Diabetes: European Commission Approves Jardiance® (Empagliflozin)

INGELHEIM, Germany & INDIANAPOLIS, US. - Friday, May 23rd 2014 [ME NewsWire]

    Empagliflozin once daily tablets approved in EU for adults with Type 2 Diabetes
    Third approved product from the Boehringer Ingelheim and Lilly Diabetes alliance

(BUSINESS WIRE) For Non-U.S. and Non-U.K. Media

The European Commission has granted Marketing Authorisation for empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor from Boehringer Ingelheim and Eli Lilly and Company. Empagliflozin has been approved for the treatment of Type 2 Diabetes (T2D) to improve glycaemic control in adults and will be marketed in Europe as Jardiance®.

The European Commission approved empagliflozin 10 and 25 mg once daily tablets for use when diet and exercise alone do not provide adequate glycaemic control:

    alone when metformin is not considered appropriate due to intolerance
    alongside other glucose-lowering medicines including insulin when glucose control is inadequate.1

“In Europe, the number of people with Type 2 Diabetes is growing and management of the condition increasingly requires a holistic approach to individuals and their needs,” said Professor Klaus Dugi, Chief Medical Officer, Boehringer Ingelheim. “We aim to bring the very latest therapy options to people living with Type 2 Diabetes and are delighted empagliflozin will become available in Europe.”

The Phase III clinical trial programme that supported empagliflozin’s Marketing Authorisation enrolled over 13,000 patients. Results from the programme showed empagliflozin 10 and 25 mg provided a significant reduction in blood sugar from baseline values. Both empagliflozin groups also demonstrated clinically relevant reductions from baseline values in body weight and blood pressure.1 When used as monotherapy, most adults did not experience side effects such as weight gain, low blood sugar and gastrointestinal issues.2 Common side effects experienced with empagliflozin were genital infection, urinary tract infection and increased urination. Genital infection and urinary tract infection were more common in women than men.3

“The approval of empagliflozin marks the third diabetes product from the Boehringer Ingelheim and Lilly Diabetes alliance to be approved in Europe,” said Enrique Conterno, President of Lilly Diabetes. “We are proud to continue with our commitment in supporting the varied treatment needs of people living with Type 2 Diabetes.”

###

Please click on the link below for ‘Notes to Editors’ and ‘References’:

http://www.boehringer-ingelheim.com/news/news_releases/press_releases/2014/23_may_2014_empagliflozin.html

Contacts

Marco Winkler

Product Communication Manager

Boehringer Ingelheim GmbH

Email: press@boehringer-ingelheim.com

Phone: +49 (151) 689 46812



Tammy Hull

Communications Manager

Lilly Diabetes

Email: hullta@lilly.com

Phone: +1 (317) 651 9116







Permalink: http://www.me-newswire.net/news/11081/en